Key clinical point: A new drug class safely cut LDL cholesterol with biannual injections in a phase 3 study.
Major finding: Four inclisiran injections administered over 15 months cut baseline LDL cholesterol levels by 50% throughout the study period.
Study details: ORION-11, a multicenter, randomized, phase 3 study with 1,617 patients.
Disclosures: ORION-11 was sponsored by the Medicines Company, which is developing inclisiran. Dr. Ray is a consultant to it and to several other companies.
REPORTING FROM THE ESC CONGRESS 2019